Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome


Bittner V. A. , Szarek M., Aylward P. E. , Bhatt D. L. , Diaz R., Edelberg J. M. , ...Daha Fazla

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, cilt.75, sa.2, ss.133-144, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 75 Konu: 2
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.jacc.2019.10.057
  • Dergi Adı: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
  • Sayfa Sayıları: ss.133-144

Özet

BACKGROUND Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C).